Enoxaparine treatment enhanced angiogenic activity of mouse and human serum

Central-European Journal of Immunology

Volumn 31, Issue 1-2, 2006, Pages 6-10

  Jung, Leszek ^a   Skopińska Rózewska, Ewa ^b   Małdyk, Paweł ^a   Sommer, Ewa ^b   Wojciechowska, Bozena ^a   Chorostowska Wynimko, Joanna ^c   Bany, Janusz ^d   Siwicki, Andrzej K ^e   Lisowska, Barbara ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^d MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

^e UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Angiogenesis; Enoxaparine; Hip surgery; Mice; Patients

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HIP SURGERY; HUMAN; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; SERUM;

EID: 33750427562     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Folkman J, Taylor S, Spillberg C: The role of heparin in angiogenesis. In: Development of the vascular system. Pitman books, London (Ciba Foundation symposium 100) 1983, 132-149.
2. Jung L, Siwicki AK, Skopińska-Różewska E, et al. (2005): Enoxaparine increases and fraxiparine decreases angiogenic activity of murine serum independently of the strain of mice. Pol J Environm Studies 14 (suppl II): 564-568.
3. Geiger F, Bertram H, Berger I, et al. (2005): Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 20: 2028-2035.
4. Sojo K, Sawaki Y, Hattori H, et al. (2005): Immunohistochemical study of vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2, -4 (BMP-2, -4) on lengthened rat femurs. J Craniomaxillofac Surg 33: 238-245.
5. Rabie AB, Lu M (2004): Basic fibroblast growth factor up-regulates the expression of vascular endothelial growth factor during healing of allogeneic bone graft. Arch Oral Biol 49: 1025-1033.
6. Eckardt H, Ding M, Lind M, et al (2005): Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br 87: 1434-1438.
7. Norrby K, Ostergaard P (1997): A 5.0-kD heparin fraction systemically suppresses VEGF165 - mediated angiogenesis. Int J Microcirc Clin Exp 17: 314-321.
8. Pisano C, Aulicino C, Vesci L, et al. (2005): Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 15: 1C-6C.
9. Christopherson KW, Campbell JJ, Travers JB, Hromas RA (2002): Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. Pharmacol Exp Therapeut 302: 290-295.
10. Savu S.R, Silvestro L (2003): Adhesion inhibition "in vitro" by heparin derivatives correlates with their activity on angiogenesis in mice. J Cell Mol Med 7: 187-191.
11. Barcz E, Skopińska-Różewska E, Kamiński P, et al. (2002): Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int J Gynaecol Obstet 79: 229-235.
12. Skopiński P, Szaflik J, Duda-Król B, et al. (2004): Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. Int J Mol Med 14:707-711.
13. Karayiannakis AJ, Zbar A, Polychronidis A, Simopoulos C (2003): Serum and drainage fluid VEGF levels in early surgical wounds. Eur Surg Res 35: 492-496.
14. Colwell AS, Beanes SR Soo C, et al. (2005): Increased angiogenesis and expression of VEGF during scarless repair. Plast Reconstr Surg 115: 204-212.
15. Curigliano G, Petit JY, Bertolini F, et al. (2005): Systemic effects of surgery: quantitative analysis of bFGF, VEGF and TGF-beta in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat 93: 35-40.
16. East MA, Landis DI, Thompson MA, Annex BH (2003): Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors. Am J Cardiology 91: 1234-1242.
17. Wasiutyński A, Skopińska-Różewska E, Jung L, et al. (2006): Comparison of the effects of enoxaparine and nadroparine on tumor angiogenesis in mice. Central Eur J Immunol (in press).
18. Mousa SA (2004): Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 22: 121-134.
19. Mousa SA, Mohamed S (2004): Inhibition of endothelial cell tube formation by the low-molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 92: 627-633.
20. Norrby K, Ostergaard P (1996): Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 16: 8-15.
21. Norrby K (2000): 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol 81: 191-198.